Anagliptin Monotherapy for Six Months in Patients With Type 2 Diabetes Mellitus and Hyper-Low-Density Lipoprotein Cholesterolemia Reduces Plasma Levels of Fasting Low-Density Lipoprotein Cholesterol and Lathosterol: A Single-Arm Intervention Trial

BACKGROUND: Anagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, has been shown to decrease plasma low-density lipoprotein cholesterol (LDL-C) levels. The objective of our study was to elucidate the mechanisms responsible for the anagliptin-mediated improvements in high LDL-C levels (hyper-LDL ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikegami, Yuichi, Takenaka, Yasuhiro, Saito, Daigo, Shimada, Akira, Inoue, Ikuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670767/
https://www.ncbi.nlm.nih.gov/pubmed/34925661
http://dx.doi.org/10.14740/jocmr4623

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670767/
https://www.ncbi.nlm.nih.gov/pubmed/34925661
http://dx.doi.org/10.14740/jocmr4623

Ejemplares similares